Tempus AI won FDA clearance for ECG-PH, AI-enabled software that analyzes standard 12-lead ECGs to flag signs of pulmonary hypertension in symptomatic patients age 40 and older with no known history of the disease. The cardiology clearance expands Tempus' FDA-cleared device portfolio to three as the company continues to build out Heart disease tools alongside its core oncology business.

Why It Matters To Oncology

• Tempus remains oncology-first, but its expanding cardiovascular AI footprint could strengthen broader clinical workflow integration across health systems that also use its cancer diagnostics and data platforms.

• The company recently agreed to acquire Personalis for $1.5 billion, bringing molecular residual disease capabilities in-house as it pushes deeper into cancer recurrence monitoring and precision oncology.

• For oncology drug discovery audiences, the signal is strategic diversification: Tempus is extending its AI, diagnostics and regulatory playbook beyond cancer while keeping oncology as the commercial anchor.

The Financials

• No financial terms were tied to the FDA clearance itself.

• The bigger capital move is Tempus' $1.5 billion Personalis acquisition, aimed at expanding its oncology testing portfolio.

• ECG-PH is Tempus' third FDA-cleared cardiology device, following ECG-AF and ECG-Low EF.

What They're Saying

• Brandon Fornwalt, Tempus' senior vice president of cardiology, said the company is “building tools that can help clinicians surface risk earlier.”

• He added pulmonary hypertension has “historically been underdiagnosed because early symptoms are non-specific and gold-standard diagnostics are invasive.”

• Tempus says ECG-PH is not a standalone diagnostic and should be interpreted with the original ECG, symptoms, other test results and clinical history.

What's Next

• Watch for adoption in cardiology and multispecialty health systems, especially where Tempus already has oncology relationships.

• Clinically, the focus will be whether AI-enabled ECG triage can help identify patients earlier for confirmatory workups such as echocardiography and right heart catheterization.

• Strategically, investors and clinicians will be watching how Tempus balances a growing Heart disease portfolio with its oncology and drug discovery ambitions.